pharma

YOU MIGHT BE INTERESTED IN

Global Anti-Obesity Treatments Market 2010-2025
Prevalence of obesity in the US and Europe has already reached high levels, with obesity being described as an epidemic and a "public health time-bomb". The developing world is also showing rising prevalence of obesity, now considered a serious - even life-threatening - disorder. In this report, we predict that the anti-obesity drug market will exhibit overall growth in worldwide revenues from 2010 to 2025, with new drugs entering the market during those years. Where will the best commercial prospects lie? Our new study provides the answers that you require.
...more details
The Global Anti-Addiction Market, 2008-2023
The global addiction market is significantly undervalued. The world's population has a large unmet need for addiction therapy drugs. Are you ready for the opportunities this presents? The brand new report, The Global Anti-Addiction Market, 2008-2023, provides an in-depth analysis of the current state of the market for addiction therapy drugs, from the present looking forward.
...more details
World Diabetes Market Analysis, 2009-2023
Incidence and prevalence of diabetes mellitus are increasing worldwide, in line with lifestyle changes and population aging. In particular, the rising prevalence of diabetes is closely linked with that of obesity, creating significant market opportunities. The World Health Organization estimates the number of diabetics to exceed 350 million by 2030. Governments and other healthcare providers around the world are investing in health education, diagnosis and treatments for this chronic, debilitating - but controllable - disorder.
...more details
The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023
Visiongain have the pleasure of announcing the latest edition of their industry leading report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the world OTC market at present and predicts its sales revenues and trends from 2008-2023, including drivers and restraints on the market.
...more details
Statins: The World Market, 2009-2024
The world statins market is changing, with patent expires and maturity of the landmark product Lipitor (atorvastatin). Statins are at the forefront of strategies to combat dyslipidaemia, being pivotal in the prevention of coronary heart disease. Consequently, those drugs are one of the most widely-prescribed and most lucrative sectors of the pharmaceutical industry, with total revenues exceeding $26 billion in 2008.
...more details
Smoking Cessation Report, 2009-2024
Smoking is the leading cause of preventable death in the world. The effects of smoking represent a global pandemic of enormous proportions. Currently-marketed smoking cessation aids typically lack high levels of efficacy in practice and are associated with marked side-effects. There are clear market opportunities for novel, more-efficacious and safer smoking cessation agents, in both prescription and OTC forms.
...more details

REPORT

...see all

Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024

Download report Download sample

Publication date: 23/02/2009
Number of Pages: 175

Report Details
Table of Contents
Companies Listed

Report Details

Obesity has been described as a 'public health time-bomb'. In 2005, the World Health Organization estimated that approximately 400 million individuals are obese. Prevalence of obesity is rising worryingly in many countries, despite campaigns emphasising the link between being overweight and contracting diabetes. This new report - Anti-Obesity Treatments 2009-2024 – explains those trends in commercial terms. In two of the largest national markets for anti-obesity treatments - the US and UK - over 20% of the population are seriously overweight. Obesity is a major risk factor in a number of other serious disorders, particularly diabetes and heart disease. Importantly, the financial burden of obesity and its associated conditions - both direct and indirect costs - are vast. Obesity is a serious, chronic condition with an emerging market for therapeutic products, as we show in this study. High socioeconomic costs and increasing prevalence are inspiring government initiatives to deal with the problem, with obesity becoming one of the most prominent global health concerns worldwide. Visiongain recognizes the contribution of drugs in this important emerging market, as diet and exercise are frequently not successful alone. We predict that new classes of drugs will invigorate the market - driving total sales in the next decade. In this report you will find out about those treatments, especially their sales potential.

Drug sales in the global anti-obesity market approached $2bn in 2008, with the market to grow substantially over the forecast period 2009-2024. This growth will be associated with a complex environment of label changes, reformulations, patent expiry, OTC switching and new product launches. Those opportunities are highlighted by the extensive R&D pipeline, crowded with novel therapies to improve treatment of obesity. Which new treatments have blockbuster potential? Our report will cover this and other important matters. Importantly, too, prevalence of obesity is rising in Latin America, India and China in particular – important pharmaceutical markets covered here.

Anti-Obesity Treatments 2009-2024 provides detailed analysis of the global anti-obesity market, with comprehensive sales forecasting. With a rigorous study of sources, including commercial databases, company reports, industry news and first-hand interviews with experts in the obesity sector, this report is a unique opportunity to discover how your company can develop over the next 5 years. The result is a comprehensive market- and industry-based report with detailed analyses and informed opinion that you will not find anywhere else.

Anti-Obesity Treatments 2009-2024 highlights the following essential aspects of the market:
• A global forecast for the anti-obesity drugs market with comprehensive discussions
• Sales forecasts for the current-leading drugs
• Assessment of new drug releases, both therapeutically and commercially
• Sales forecasts for the leading national anti-obesity markets, as well as for emerging national markets
• Discussion of strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the anti-obesity drug sector
• Extensive analysis of pipeline developments, including avenues for future research
• Discussion of current un-met and under-met needs in the anti-obesity market, revealing both therapeutic needs and commercial opportunities.

Why you should buy this report:
• To receive a comprehensive analysis of the prospects for anti-obesity therapies from 2009-2024, including predicted revenues, growth rates and other key metrics
• To identify key pipeline developments, the most promising therapy classes and potential methods of treatment
• To discover the important drivers and restraints for the global anti-obesity market, including factors affecting leading national markets
• To find out where the global anti-obesity market is heading - both technologically and commercially - from the present onwards.

This report is essential reading for anyone in the pharmaceutical and healthcare sector with an interest in obesity and related conditions. Purchasing this report will help you to recognise those important market opportunities and understand the possibilities there.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1 Executive Summary: Anti-Obesity Treatments 2009-2024

2 An Introduction to Obesity and Its Treatment
2.1 What is Obesity?
2.1.1 Fat is a Necessary Component of the Body
2.1.2 Obesity is a Chronic Disease
2.1.3 Body Weight is Dependent upon Several Factors
2.2 How is Obesity Measured?
2.2.1 Weight-for-Height Tables
2.2.2 Waist Circumference
2.2.3 Body Mass Index (BMI)
2.3 How Serious is the Problem?
2.3.1 Prevalence
2.3.2 Risk Factors of Other Diseases (Co-Morbidities)
2.3.3 Economic Costs
2.4 Historical Causes and Lifestyle Changes
2.4.1 Urbanisation, Modernisation and Economic Development
2.4.2 Developed Countries and in Developing Nations
2.5 Factors Causing Obesity
2.5.1 Lifestyle, Environment and Diet
2.5.2 Behaviour
2.5.3 Psychological Factors
2.5.4 Genetics
2.5.5 Antecedent Illnesses and Treatments
2.5.6 Other Causes
2.6 Treatment of Obesity
2.6.1 Lifestyle and Behavioural Changes
2.6.2 Unapproved Drugs
2.6.3 Alternative Therapies
2.6.4 Pharmacotherapy
2.6.5 Surgical Options
2.6.6 Drugs have a Role in the Treatment of Obesity.
2.7 Pharmacotherapy in the Treatment of Obesity
2.7.1 Lipase Inhibitors
2.7.2 Anorectic Drugs
2.7.3 Off-Label Use of Drugs
2.8 Need for Future Development in the Treatment of Obesity
2.8.1 Unmet Needs and Market Potential

3 The World Market for Anti-Obesity Drugs, 2009-2024
3.1 The Current Anti-Obesity Market Climate - a Potential Blockbuster Market
3.2 Leading Companies in the Anti-Obesity Market
3.3 Market History and the Current Situation
3.3.1 The Effect of Pondimin, Redux and Public Opinion on the Anti-Obesity Market
3.3.2 Rimonabant and other Cannabinoid Receptor Antagonists
3.3.3 Phentermine
3.4 Total Anti-Obesity Market Forecast 2009-2024
3.4.1 Market Growth in 2009-2024
3.4.2 Drugs after 2012
3.5 Xenical Forecast 2009-2024
3.5.1 Will Generic Erosion Drive Down Xenical's Sales?
3.5.2 Competition Increases with New Releases
3.5.3 Will Xenical be Driven Out by Newer Rivals?
3.6 Reductil/Meridia Forecast 2009-2024
3.6.1 How Will Competition Affect Sales?
3.6.2 Expiry of Patents in 2013
3.7 Alli Forecast 2009-2024
3.7.1 Early Launch-Stocking
3.7.2 European Launch
3.7.3 Is Alli Failing to Distinguish Itself?
3.8 Dinintel Forecast 2009-2024
3.8.1 Will the Rapidly Evolving Anti-Obesity Market Will Leave Dinintel Behind?
3.9 Total Other Drugs Forecast 2009-2024
3.9.1 Generic Competitors
3.9.2 New Drug: Contrave (Orexigen)
3.9.3 New Drug: Lorcaserin (Arena)
3.9.4 New Drug: Qnexa (Vivus)
3.9.5 New Drug: Liraglutide (Novo Nordisk)
3.9.6 New Drug: Empatic/Excalia (Orexigen)
3.10 Market Summary
3.10.1 New Drugs and the Market
3.10.2 Lack of Innovation and the Market Opportunities?
3.10.3 The Problems with Anorectic Drugs
3.10.4 The Problems with Lipase Inhibitors
3.10.5 The Future of Anti-Obesity Treatments

4 Anti-Obesity Treatments - SWOT Analysis
4.1 Strengths
4.1.1 Long-Term Therapy with Anti-Obesity Drugs
4.1.2 Prospects of Multiple Indications for Anti-Obesity Drugs
4.1.3 Off-Label Potential and Competition
4.1.4 The Anti-Obesity Market is Ready to be Revolutionised
4.1.5 Failure of Rimonabant Leaves Vacuum in the Market
4.1.6 New Drugs May Not Fill the Entirety of Customer Needs
4.2 Weaknesses
4.2.1 Limited Efficacy
4.2.2 Undesirable Side-Effects Limit Market Potential of Anti-Obesity Medications
4.2.3 Increased Competition by both Impending New Releases and Generic Competitors
4.2.4 Regulatory Hurdles have Become Stricter - Companies Pay the Price
4.2.5 Pharmacotherapy Will Never be the First Line of Treatment?
4.3 Opportunities
4.3.1 Rising Prevalence Drives Market Potential
4.3.2 Unmet Market Needs - Can Drugs Solve this Problem?
4.3.3 A Safe and Effective Anti-Obesity Treatment has Applications in Both the Clinical and Cosmetic Sectors
4.3.4 How the Changing Government Agenda and the High Economic Costs of Obesity Will Drive Growth in the Anti-Obesity Market
4.3.5 Diet and Exercise May be the Mainstay Treatment, but this Approach is not Always Effective
4.4 Threats
4.4.1 Reimbursement May Continue to be a Limiting Factor
4.4.2 Long-Term Safety Issues Continue to Stunt Growth
4.4.3 Opinion of Both the Public and Prescribing Bodies is Heavily Dependent upon Individual Drug Successes and Success of the Market as a Whole
4.4.4 Will Healthier Lifestyles Limit the Current Need for Anti-Obesity Drugs?

5 Pipeline Developments in Anti-Obesity Treatments
5.1 Treatments in Phase III
5.1.1 Lorcaserin
5.1.2 Qnexa
5.1.3 Contrave
5.1.4 Cetilistat
5.2 Treatments in Phase II
5.2.1 Empatic/Excalia
5.2.2 Liraglutide
5.2.3 Obinepitide
5.2.4 Solabegron
5.2.5 Tesofensine
5.2.6 Velneperit
5.2.7 Histalean
5.2.8 Sodium Tungstate
5.2.9 Serglifozin Etabonate
5.2.10 Pramlintide & Metreleptin
5.2.11 Hoodia gordonii Extract
5.2.12 MTP Inhibitor
5.2.13 TM 30339
5.2.14 SLx 4090
5.2.15 MK 0493
5.2.16 KRP 204
5.2.17 FM VP4
5.2.18 AZD 2207
5.2.19 CE 326597
5.3 Treatments in Phase I
5.3.1 Trodusquemine
5.3.2 THCV
5.3.3 Oral PYY3-36
5.3.4 ATHX 105
5.3.5 AZD 1175
5.3.6 AZD 1656
5.3.7 BVT 74316
5.3.8 CP 404
5.3.9 KD 3010
5.3.10 PRX 07034
5.3.11 PSN 602
5.3.12 TKS 1225
5.3.13 V 24343
5.3.14 TTP 435
5.4 Other Promising Pipeline Developments
5.4.1 Melanotan
5.4.2 Increasing Mitochondrial Activity to Increase Energy Expenditure
5.4.3 Inhibiting the Creation of Fat Stores after Gut Absorption

6 Obesity in the Leading World Markets
6.1 The Total Market for Anti-Obesity Treatments
6.1.1 Drug Development Will Drive the Market
6.2 US Anti-Obesity Market Forecast 2009-2024
6.2.1 Patent Expiries and New Drug Releases Will Create a Turbulent Market
6.2.2 Will The Market Show Uninhibited Growth During the Forecast Period?
6.3 Mexico Anti-Obesity Market Forecast 2009-2024
6.3.1 The Health Care System Currently Limits Treatment Accessibility
6.3.2 Prevalence of Obesity Driving the Market
6.4 Brazil Anti-Obesity Market Forecast 2009-2024
6.4.1 Increasing Prevalence Will Force an Increase in Sales over the Forecast Period
6.5 UK Anti-Obesity Market Forecast 2009-2024
6.5.1 Lagging Sales Will Turn to Positive Growth in the Early Forecast Period
6.5.2 Government Agenda Will Support Growth of Anti-Obesity Treatments in the UK
6.6 South Korea Anti-Obesity Market Forecast 2009-2024
6.6.1 Government Agenda Will Maintain High Sales
6.7 Spain Anti-Obesity Market Forecast 2009-2024
6.7.1 New Drug Releases and Patent Expiries
6.7.2 The Market Will Show Consistent Positive Growth
6.8 France Anti-Obesity Market Forecast 2009-2024
6.8.1 Reimbursement will Drive Sales
6.9 Total Other Countries Anti-Obesity Market Forecast 2009-2024
6.9.1 Total Other Countries Sales
6.9.2 The Impact of Emerging Markets
6.9.3 Emerging Market: India
6.9.4 Emerging Market: China

7 Experts' Views on the Main Issues in the Treatment of Obesity
7.1 An Interview with Dr. Tyrberg from The Burnham Institute Diabetes and Obesity Research Centre
7.1.1 The Effect of Anti-Obesity Drugs on the Obese Population
7.1.2 The Cause-Effect Relationship between Diet, Obesity and Type 2 Diabetes
7.1.3 Off-Label Indications and Diabetes Treatments Used to Treat Obesity
7.1.4 Obesity as a Lifestyle Disease?
7.1.5 The Future of Anti-Obesity Treatments and the Role Diet and Exercise Will Play
7.1.6 The Role of Pharmaceutical Companies, Ethics and the Cosmetic Use of Anti-Obesity Treatments
7.1.7 Unmet Medical Needs in the Treatment of Obesity
7.1.8 The Future of the Anti-Obesity Market
7.2 Commentaries and Views from Other Experts in the Field
7.2.1 The Most Important Unmet Medical Needs in the Treatment of Obesity
7.2.2 The Future of Anti-Obesity Treatment
7.2.3 Funding of Anti-Obesity Treatments
7.2.4 The Anti-Obesity Market in Developing Nations
7.2.5 Concluding Thoughts

8 Conclusions
8.1 Obesity is a Chronic Disease with Serious Health Implications
8.2 The Prevalence and Economic Costs of Obesity
8.3 The Modern Lifestyle has Contributed Significantly to Obesity
8.4 Obesity is Caused by a Complex Interplay of Factors
8.5 Obesity Treatments and the Role of Pharmaceuticals
8.6 The Unmet Needs and Market Potential for Anti-Obesity Treatments
8.7 The Anti-Obesity Market Will Expand from 2009-2024
8.8 The Main Drivers and Restraints of the Anti-Obesity Market
8.9 Geographical Overview of the Anti-Obesity Market
8.10 Outlook for the Future

Appendices
Appendix 1: Conditions Associated with Obesity
Appendix 2: Bariatric Surgery Options
Appendix 3: About visiongain
Appendix 4: Visiongain Report Evaluation Form

List of Tables
Table 2.1 - BMI Classification Bands
Table 2.2 - Obesity Prevalence Amongst US Adults 1991-2007
Table 3.1 - Leading Anti-Obesity Drugs in Sales ($m), Market Share (%) and Growth (%), 2007
Table 3.2 - Leading Companies for Anti-Obesity Drugs in Sales ($m) and Market Share (%), 2007
Table 3.3 -Total Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
Table 3.4 - Total Anti-Obesity Market CAGR Values (%), 2009-2024
Table 3.5 - Xenical Forecast in Sales ($m) and Growth (%), 2009-2024
Table 3.6 - Xenical CAGR Values (%), 2009-2024
Table 3.7 - Reductil/Meridia Forecast in Sales ($m) and Growth (%), 2009-2024
Table 3.8 - Reductil/Meridia CAGR Values (%), 2009-2024
Table 3.9 - Alli Forecast in Sales ($m) and Growth (%), 2009-2024
Table 3.10 - Alli CAGR Values (%), 2009-2024
Table 3.11 - Dinintel Forecast in Sales ($m) and Growth (%), 2009-2024
Table 3.12 - Dinintel CAGR Values (%), 2009-2024
Table 3.13 - Total Other Drugs Forecast in Sales ($m) and Growth (%), 2009-2024
Table 3.14 - Total Others Drugs CAGR Values (%), 2009-2024
Table 4.1 - SWOT Chart of the Anti-Obesity Market, 2009-2024
Table 5.1 -The Anti-Obesity Pipeline 2009
Table 6.1 - US Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
Table 6.2 - US Anti-Obesity Market CAGR Values (%), 2009-2024
Table 6.3 - Mexico Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
Table 6.4 - Mexico Anti-Obesity Market CAGR Values (%), 2009-2024
Table 6.5 - Brazil Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
Table 6.6 - Brazil Anti-Obesity Market CAGR Values (%), 2009-2024
Table 6.7 - UK Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
Table 6.8 - UK Anti-Obesity Market CAGR Values (%), 2009-2024
Table 6.9 - South Korea Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
Table 6.10 - South Korea Anti-Obesity Market CAGR Values (%), 2009-2024
Table 6.11 - Spain Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
Table 6.12 - Spain Anti-Obesity Market CAGR Values (%), 2009-2024
Table 6.13 - France Anti-Obesity Market CAGR Values (%), 2009-2024
Table 6.14 - France Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
Table 6.15 - Total Other Countries Anti-Obesity Market Forecast in Sales ($m) and Growth (%), 2009-2024
Table 6.16 - Total Other Countries Anti-Obesity Market CAGR Values (%), 2009-2024
Table A2.1 - Bariatric Surgery Options

List of Figures
Figure 2.1 - Obesity Prevalence Amongst US Adults 1991-2007
Figure 3.1 - Leading Anti-Obesity Drugs Sales ($m), 2007
Figure 3.2 - Leading Anti-Obesity Drugs Market Share (%), 2007
Figure 3.3 - Leading Companies of Anti-Obesity Drugs Sales ($m), 2007
Figure 3.4 - Leading Companies Anti-Obesity Market Share (%), 2007
Figure 3.5 - Total Anti-Obesity Market Sales ($m), 2009-2024
Figure 3.6 - Xenical Sales ($m), 2009-2024
Figure 3.7 - Reductil/Meridia Sales ($m), 2009-2024
Figure 3.8 - Alli Sales ($m), 2009-2024
Figure 3.9 - Dinintel Sales ($m), 2009-2024
Figure 3.10 - Total Other Drugs Sales ($m), 2009-2024
Figure 3.11 - All Drugs Market Share (%), 2009-2024
Figure 6.1 - Total Anti-Obesity Market Sales ($m), 2009-2024
Figure 6.2 - US Anti-Obesity Market Forecast Sales ($m), 2009-2024
Figure 6.3 - Mexico Anti-Obesity Market Forecast Sales ($m), 2009-2024
Figure 6.4 - Brazil Anti-Obesity Market Forecast Sales ($m), 2009-2024
Figure 6.5 - UK Anti-Obesity Market Forecast Sales ($m), 2009-2024
Figure 6.6 - South Korea Anti-Obesity Market Forecast Sales ($m), 2009-2024
Figure 6.7 - Spain Anti-Obesity Market Forecast Sales ($m), 2009-2024
Figure 6.8 - France Anti-Obesity Market Forecast Sales ($m), 2009-2024
Figure 6.9 - Total Other Countries Anti-Obesity Market Forecast Sales ($m), 2009-2024
Figure 6.10 - Anti-Obesity Combined Country Forecast Sales ($m), 2009-2024
Figure 6.11 - Anti-Obesity Market Country Market Share Forecast (%), 2009-2024
Figure 8.1 - Total Anti-Obesity Market Sales ($m), 2009-2024
Figure 8.2 - Anti-Obesity Drugs Forecast by Market Share (%), 2009-2024
Figure 8.3 - Anti-Obesity Combined Country Forecast Sales ($m), 2009-2024
Figure 8.4 - Anti-Obesity Market Country Market Share Forecast, 2009-2024

Companies Listed

7TM Pharma
Abbott
Ache Laboratories
Actavis
Alizyme
American Home Products
Amylin
Arena
AstraZeneca
Athersys
Barcelona University
Bayer
Biovitrum
Bristol-Myers Squibb
Clinuvel
Compellis
Council for Scientific and Industrial Research
Duke University
Eli Lilly
EMEA
Emisphere
EMS
Epix
FDA
Forbes Medi-Tech
Gate Pharmaceuticals
Genaera
GlaxoSmithKline
Graceway Pharma
GW Pharmaceuticals
Han Wha
Hanmi
Inova Pharma
Johnson & Johnson
Kalypsys
Kissei
Kyorin
Louisiana State University
Medley
Merck & Co.
NeuroSearch
Novartis
Novo Nordisk
Nycomed Pharma
OBEcure
Orexigen
OSI Pharmaceuticals
Pfizer
Phytopharm
Roche
Sanofi-Aventis
Shionogi
Sirtris Pharmaceuticals
Solvay
Surface Logix
Takeda
Teva
The Burnham Institute
Transition
TransTech
URL Pharma
Vernalis
Vivus
Wyeth Pharmaceuticals

YOU MIGHT BE INTERESTED IN

Global Anti-Obesity Treatments Market 2010-2025

The Global Anti-Addiction Market, 2008-2023

World Diabetes Market Analysis, 2009-2023

The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023

Statins: The World Market, 2009-2024

Smoking Cessation Report, 2009-2024

REPORT

Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024

Report Details

Table of Contents

Companies Listed